Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 4/20 | 0.48 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458892 | 0.91 | CACNA1G (0.53) | CACNA1GPARP1MAPTHTR3ACDC42 | |
| SCHEMBL5466668 | 0.87 | MAPT (0.46) | CACNA1GMAPTMAPK1ALOX15SMN1; SMN2 | |
| SCHEMBL5466557 | 0.87 | HTR3A (0.51) | CACNA1GPARP1MAPTMAPK1ALOX15 | |
| SCHEMBL5456555 | 0.87 | GAA (0.53) | CACNA1GPARP1MAPTHTR3ACDC42 | |
| SCHEMBL5458899 | 0.86 | CACNA1G (0.52) | CACNA1GPARP1MAPTMAPK1ALOX15 | |
| SCHEMBL5492905 | 0.84 | SMN1; SMN2 (0.48) | PARP1MAPTMAPK1ALOX15SMN1; SMN2 | |
| SCHEMBL5449841 | 0.84 | CACNA1G (0.53) | CACNA1GPARP1MAPTHTR3ACDC42 | |
| SCHEMBL5454081 | 0.81 | GAA (0.52) | CACNA1GPARP1MAPTHTR3ACDC42 | |
| SCHEMBL5456598 | 0.80 | HTR3A (0.54) | CACNA1GPARP1HTR3ACDC42KMT2A | |
| SCHEMBL5454753 | 0.80 | PARP1 (0.56) | CACNA1GPARP1MAPTHTR3AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | CHIRON CORPORATION | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070276009-A1 | Compositions and Methods for Viral Inhibition | MAVS, SARS1, ZC3HAV1 | CACNA1G 4194/4885PARP1 709/4885MAPT 3817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.